

Señora

Alix Carmenza Céspedes de Vergel

Jefe de División de Nuevas Creaciones

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E. S. D.

Referencia: Expediente No. 09.022.193

Solicitud de Patente de Invención titulada: "Puerto de vendaje para herida y vendaje para herida asociado"

Solicitante: Tyco Healthcare Group LP

RESPUESTA AL AUTO NOTIFICADO POR FIJACIÓN EN LISTA NO. 104
DEL 16 DE ABRIL DE 2009, OFICIO NO. 4337 (EXAMEN DE FORMA)

ÁLVARO CORREA ORDÓÑEZ, mayor de edad y vecino de Bogotá D.C., identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, doy respuesta al auto emanado por ese Despacho dentro del término legal:

1. Presento copia debidamente legalizada del documento en que consta la cesión del derecho a la patente a la entidad solicitante por parte del inventor.
2. Presento copia certificada del documento de prioridad No. 12/044,051 de fecha 7 de marzo de 2008, sobre el cual se reclama prioridad en la presente solicitud y la traducción al español de las reivindicaciones del mismo.

Atentamente,

ÁLVARO CORREA ORDÓÑEZ

C.C.No.79.143.366 de Usaquén

T.P.20.281

Anexos: Documento de Cesión de Inventores
Documento de prioridad y traducción de reivindicaciones

BOGATM/BOGDMS-158419-V1-P2009_000043-0390.DOC

40

204

2

TRADUCCIÓN OFICIAL N° 340/2009 de un documento escrito en inglés el cual para su identificación se sella con el sello del traductor. Esta es una traducción oficial efectuada el día 10 de junio de 2009 por la señora Teresa Jiménez de Montes, con cc 41.569.149 de Bogotá, traductora oficial según Resolución N° 220 del 6 de febrero de 1978, expedida por el Ministerio de Justicia de la República de Colombia

CESIÓN

Mark A. VESS
TYCO HEALTHCARE GROUP LP
Documento escrito en inglés y español.

Firmado: Mark A. Vess

Firma de los inventores

Firmado: Vicki E. Lannigan
Notaria Pública
Mi comisión vence 7/17/09

Sello seco:
Vicki E. Lannigan
Notaria Pública
Massachusetts
Vencimiento comisión julio 17, 2009

H-KN-01015 CO

ESTADO DE MASSACHUSETTS

Bristol, suscrito y jurado

Yo, Vicki E. Lannigan, Notaria Pública para el Estado de Massachusetts, por el presente certifico que la Cesión adjunta para el Número de Solicitud Colombiano 09.022.193 es una copia fiel y correcta del documento original en todos los aspectos.

Firmado: Vicki E. Lannigan

NOTARIO PÚBLICO

Mi comisión vence: julio 17, 2009

Sello seco:
Vicki E. Lannigan
Notaria Pública
Massachusetts
Vencimiento comisión julio 17, 2009

The Commonwealth of Massachusetts

William Francis Galvin
Secretary of the Commonwealth

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America

This public document

2. has been signed by: Vicki E. Lannigan

3. acting in the capacity of: Notary Public

4. bears the seal/stamp of: the State of Massachusetts
whose commission expires on: July 17, 2009

Certified

5. at: Boston, Massachusetts

6. the: 2 June, 2009

7. by: the Secretary of the Commonwealth

8. No.: 1384445


9. Seal/stamp:

Great Seal of the Commonwealth

10. Signature:




William Francis Galvin
Secretary of the Commonwealth



COMMONWEALTH OF MASSACHUSETTS

Bristol, ss.

I, Vicki E. Lannigan, a Notary Public for the Commonwealth of Massachusetts, do hereby certify that the attached Assignment for Colombian Application Number 09.022.193 is a true and accurate copy of the original document in all respects.



Vicki E. Lannigan
NOTARY PUBLIC

My commission expires: July 17, 2009

2th
5h

ASSIGNMENT

Mark A. VESS

by means of this document assign(s) to

TYCO HEALTHCARE GROUP LP

A company organized under the laws of

Domiciled in

15 Hampshire Street, Mansfield, Massachusetts 02048,
United States of America,

all my (our) rights, title and interest in and to my (our)
invention entitled and as fully set forth and described in:
Colombian Patent Application No. 09.022.193

So far as the Republic of Colombia is concerned and any
other country in which the application is filed.

Done and subscribed in

On the 7th day of APR, of 2009

CESION

Mark A. VESS

por medio de la presente cedo (cedemos) a

TYCO HEALTHCARE GROUP LP

Una compañía organizada bajo las leyes de

domiciliada en


15 Hampshire Street, Mansfield, Massachusetts 02048,
Estados Unidos de América,

todos mis (nuestros) derechos, título e interés sobre mi
(nuestra) invención titulada y tal como describe en:
Solicitud de patente en Colombia No. 09.022.193

en lo que concierne a la República de Colombia y cualquier
otro país del mundo en donde se presente la solicitud.


Dado y firmado en

A los 7 días del mes de Abril de 2009



Mark A. VESS

Signature of the inventors



VICKI E. LANNIGAN

Notary Public

My Commission Expires 11/17/09

Mark A. VESS
Firma de los inventores

7



LOS ESTADOS UNIDOS DE AMÉRICA

A TODO AQUEL A QUIEN CONCIERNA LO PRESENTE
DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Patentes y Marcas de los Estados Unidos

20 de abril de 2009

LA PRESENTE ES PARA CERTIFICAR QUE ADJUNTA A LA MISMA HAY UNA COPIA FIEL DE LOS REGISTROS DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS DE LOS DOCUMENTOS DE LA SOLICITUD DE PATENTE IDENTIFICADA EN LO QUE SIGUE, QUE CUMPLE LOS REQUISITOS PARA OTORGARLE UNA FECHA DE PRESENTACIÓN BAJO EL 35 USC 111.

NÚMERO DE SOLICITUD: 12/044,051
FECHA DE PRESENTACIÓN: 07 de marzo de 2008

EL CÓDIGO DE PAÍS Y NÚMERO DE SU SOLICITUD DE PRIORIDAD, PARA SER USADA PARA PRESENTACIÓN EN EL EXTRANJERO DE ACUERDO CON LA CONVENCIÓN DE PARIS, ES US12/044,051



Por la Autoridad del
De acuerdo con la Secretaría de Comercio para la
Propiedad Intelectual y el Director de la Oficina de
Marcas y Patentes de los Estados Unidos

(Aparece firma ilegible)

M. K. CARTER

Funcionario Certificador

216
46

REIVINDICACIONES

Lo que se reivindica es:

1. Un vendaje para herida que comprende:

5 Una capa de respaldo para posicionar sobre una herida para definir un reservorio en el que se puede mantener una presión reducida sobre la herida; y

10 Un miembro de puerto fijo a la capa de respaldo de tal manera que una superficie ambiente del miembro de puerto se puede aislar de manera fluida de una superficie de reservorio del miembro de puerto, la capa de respaldo define un límite entre la superficie ambiente y la superficie de reservorio cuando la capa de respaldo se posiciona sobre una herida, el miembro de puerto
15 comprende:

Un puerto principal que se extiende entre una abertura en la superficie ambiente y una abertura principal en la superficie de reservorio, la abertura se adapta para conexión a un dispositivo de succión y la abertura principal se adapta para
20 establecer comunicación fluida con el reservorio; y

Por lo menos un puerto complementario que establece comunicación fluida entre el puerto principal y una abertura complementaria en la superficie de reservorio, la abertura complementaria es distinta y está sustancialmente espaciada de la
25 abertura principal.

2. El vendaje para herida de acuerdo con la reivindicación 1, en donde por lo menos un puerto complementario incluye una pluralidad de puertos complementarios, cada puerto complementario
30 se extiende radialmente hacia fuera del puerto principal.

3. El vendaje para herida de acuerdo con la reivindicación 1, en donde por lo menos un puerto complementario incluye una pluralidad de puertos complementarios, cada puerto complementario
35 se extiende entre el puerto central y una abertura complementaria respectiva en la superficie del reservorio, de tal manera que las aberturas principal y complementaria se distribuyen sustancialmente sobre la superficie completa del reservorio.

40 4. El vendaje para herida de acuerdo con la reivindicación 1, en donde el miembro de puerto se moldea de material elastomérico o polimérico flexible.

5. El vendaje para herida de acuerdo con la reivindicación 1, en donde el miembro de puerto comprende adicionalmente un reborde de unión adaptado para conexión a la capa de respaldo.

5

6. El vendaje para herida de acuerdo con la reivindicación 1, en donde la capa de respaldo comprende una membrana polimérica flexible.

10

7. El vendaje para herida de acuerdo con la reivindicación 7, en donde la capa de respaldo comprende un recubrimiento adhesivo alrededor de su periferia, el recubrimiento adhesivo se adapta para fijar la capa de respaldo sobre la herida y proporciona un sello sustancialmente hermético a los fluidos alrededor del

15

perímetro de la herida.

8. El vendaje para herida de acuerdo con la reivindicación 8, en donde el recubrimiento adhesivo se interrumpe de tal manera que una porción intermedia de la capa de respaldo permanece

20

descubierta.

9. Un sistema de terapia con vacío para herida que comprende:

Una capa de contacto adaptada para posicionarse adyacente a un lecho de herida;

25

Un relleno absorbente posicionado adyacente a la capa de contacto dentro del lecho para herida para recolectar líquidos que exudan del lecho de herida; y

30

Un miembro de puerto fijado a una capa de respaldo posicionada sobre el lecho de herida para definir un reservorio de vacío entre ellos, El miembro de puerto incluye un puerto principal que se extiende entre una abertura en una superficie ambiente y una abertura principal en una superficie de reservorio, el miembro de puerto incluye adicionalmente por lo

35

menos un puerto complementario que se extiende entre el puerto principal y una abertura complementaria en la superficie del reservorio, la abertura complementaria es distinta y está sustancialmente espaciada de la abertura principal.

40

10

10. El sistema de terapia con vacío para herida de acuerdo con la reivindicación 9, en donde la capa de contacto se forma de una película abierta cónica.
- 5 11. El sistema de terapia con vacío para herida de acuerdo con la reivindicación 9, en donde el material de relleno absorbente comprende una única hebra de un filamento de poliolefina.
- 10 12. El sistema de terapia con vacío para herida de acuerdo con la reivindicación 9, que comprende adicionalmente un sistema de vacío en comunicación fluida con un reservorio de vacío.
- 15 13. El sistema de terapia con vacío para herida de acuerdo con la reivindicación 9, en donde el sistema de vacío incluye una fuente de vacío, un frasco de recolección y una válvula de una vía.

BOGDMS-172817-V1-P2009_000043-0260_DOC

214
49

PA 7180122

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 20, 2009

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**

APPLICATION NUMBER: 12/044,051

FILING DATE: March 07, 2008

**THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY
APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS
CONVENTION, IS US12/044,051**

By Authority of the

**Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office**

M. K. CARTER

Certifying Officer



Electronic Acknowledgement Receipt

EFS ID:	2963407
Application Number:	12044051
International Application Number:	
Confirmation Number:	6461
Title of Invention:	WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING
First Named Inventor/Applicant Name:	Mark A. Vess
Customer Number:	55825
Filer:	Joseph W. Schmidt
Filer Authorized By:	
Attorney Docket Number:	HKN-01015 (1502-323)
Receipt Date:	07-MAR-2008
Filing Date:	
Time Stamp:	10:55:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1030
RAM confirmation Number	7922
Deposit Account	190254
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

13

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	AppDataSheet.pdf	1009367 af002c16b1df5d13fa4d429225b4c1702c22817c	no	4

Warnings:**Information:**

2		HKN01015Application.pdf	581644 6d621648c1eec8f7eadab334f787d81c640855b4	yes	16
---	--	-------------------------	--	-----	----

Multipart Description/PDF files in .zip description

Document Description	Start	End
Specification	1	12
Claims	13	15
Abstract	16	16

Warnings:**Information:**

3	Drawings-only black and white line drawings	HKN01015Figs.pdf	88315 b1c6e7220aa124ce190a0692c89d4ede07031317	no	3
---	---	------------------	---	----	---

Warnings:**Information:**

4	Oath or Declaration filed	HKN01015Dec.pdf	237420 d2855a9f65a0d2b898a42dd9c1105e6b65282df9	no	6
---	---------------------------	-----------------	--	----	---

Warnings:**Information:**

5	Fee Worksheet (PTO-06)	fee-info.pdf	8373 e9dccc4771ddc8797c41c7b8ef0bd6c80b14cod6d	no	2
---	------------------------	--------------	---	----	---

Warnings:**Information:**

Total Files Size (in bytes):			1925119		
-------------------------------------	--	--	---------	--	--

52

14
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING

BACKGROUND

1. Technical Field

5 The present disclosure relates generally to a wound dressing for treating an open wound with a vacuum wound therapy treatment. In particular, the disclosure relates to a dressing having a portal member providing a connection to a vacuum system such that a reservoir over the wound may be evacuated.

2. Background of Related Art

10 The body's natural wound healing process is a complex series of events beginning at the moment of injury. Initially the body reacts by delivering proteins and other factors to the wound through the blood stream to minimize the damage. Blood clots to prevent blood loss while cells engulf bacteria and debris to carry it away from the wound site. Next, the body begins to repair itself in a stage of healing often referred to as the proliferative phase. This phase is characterized
15 by the deposition granulation tissue in the wound bed. Granulation tissue provides a base structure over which cells may migrate inwardly from the periphery to close the wound. Finally the process ends as collagen gives strength to new tissue over time often forming a scar.

One technique for promoting the natural healing process, particularly, but not exclusively during the proliferative phase, is known as vacuum wound therapy (VWT). Application of a
20 reduced pressure, e.g. sub-atmospheric, to a localized reservoir over a wound has been found to assist in closing the wound. The reduced pressure may be effective to promote blood flow to the

area to stimulate the formation of granulation tissue and the migration of healthy tissue over the wound by the natural process. Also a reduced pressure may assist in removing fluids exuding from the wound, which may inhibit bacterial growth. This technique has proven effective for chronic or non-healing wounds, but has also been used in for other purposes such as post-operative wound care.

The general VWT protocol provides for the introduction of an absorbent filler material, such as non-reticulated foams, non-woven fabrics, or gauze, into the wound to absorb exudates. The wound and the absorbent filler material may then be overlaid by a flexible cover layer such as a polymeric film, for example, to establish a vacuum reservoir over the wound where a reduced pressure may be applied by individual or cyclic evacuation procedures. To allow the reduced pressure to be maintained over time, the cover layer may include an adhesive periphery that forms a substantially fluid tight seal with the healthy skin surrounding the wound.

Although some procedures may employ a micro-pump contained within the vacuum reservoir, most VWT treatments apply a reduced pressure using an external vacuum source. Thus, fluid communication between the vacuum source and the reservoir must be established. To this end, a cover layer will often include a connector or portal member to which air hoses from an external vacuum system may be connected.

An aspect of concern in a VWT treatment is the migration of the filler material and wound exudates in the direction of airflow when the reduced pressure is applied. These substances may be deposited on surfaces within a portal member, for example, and over time cause the obstruction or complete occlusion of these portal members. This phenomenon may limit the level of exudate flow from the wound area, or may even prohibit the application of a

17
reduced pressure to the wound area, thus limiting or defeating the effectiveness of the VWT treatment. Accordingly, a need exists for a dressing suitable for use in a VWT procedure.

SUMMARY

The present disclosure describes a wound dressing for use in a vacuum wound therapy treatment. The wound dressing includes a backing layer for positioning over a wound to define a reservoir in which a reduced pressure may be maintained over the wound. A portal member is affixed to the backing layer such that an ambient surface of the portal member may be fluidly isolated from a reservoir surface of the portal member. The backing layer defines a boundary between the ambient surface and the reservoir surface when the backing layer is positioned over a wound. The portal member comprises a primary port extending between an opening in the ambient surface and a primary aperture in the reservoir surface. The opening is adapted for connection to a suction device and the primary aperture is adapted for establishing fluid communication with the reservoir. The portal member further comprises at least one supplemental port establishing fluid communication between the primary port and a supplemental aperture in the reservoir surface. The supplemental aperture is distinct and substantially spaced from the primary aperture.

The portal member may include a plurality of supplemental ports extending radially outwardly from the primary port. The primary and supplemental apertures may be distributed substantially over the entire reservoir surface. The may be molded from a flexible polymeric or elastomeric material and may include an attachment flange adapted for connection of an adhesively coated film.

The backing layer of the wound dressing may comprise a flexible polymeric membrane. The backing layer may include an adhesive coating adapted to affix the backing layer over the wound and to provide a substantially fluid tight seal around the perimeter of the wound. The adhesive coating may be interrupted such that an intermediate portion of the backing layer
5 remains uncoated.

According to a further aspect of the disclosure, a vacuum wound therapy system includes a contact layer and an absorbent filler positioned in a wound bed, and a portal member affixed to a backing layer positioned over the wound bed to define a vacuum reservoir. The portal member includes a primary port extending between an opening in an ambient surface and a primary
10 aperture in a reservoir surface, and at least one supplemental port extending between the primary port and a supplemental aperture distinct and substantially spaced from the primary aperture.

The contact layer may be formed from a conical apertured film to promote unidirectional flow of exudates from the wound. The absorbent filler material may include a single strand of a polyolefin filament. Also, a vacuum system in fluid communication with the vacuum reservoir
15 may include a vacuum source, a collection canister and a one-way valve.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.

20 FIG. 1 is an exploded perspective view of a vacuum wound therapy system in accordance with the present disclosure;

FIG. 2 is an orthographic view of a wound facing side of the portal member of FIG. 1;

FIG. 3 is a cross sectional view taken along the line 3-3 of FIG. 2;

FIG. 4 is a cross sectional view of the vacuum wound therapy system of FIG. 1 installed over wound on a patient; and

5 FIG. 5 is a view similar to FIG. 4 depicting an alternate embodiment of a vacuum wound therapy system.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The wound dressing of the present disclosure promotes healing of a wound by providing a reservoir over the wound where a reduced pressure may be maintained. The reservoir subjects
10 the wound to a sub-atmospheric pressure to effectively draw wound fluid, including liquid exudates, from the wound without the continuous use of a vacuum pump. Hence, vacuum pressure may be applied once, or in varying intervals depending on the nature and severity of the wound. The use of a wound dressing in this manner has been found to promote healing by reducing the probability of infection, stimulating the deposition of granulation tissue and other
15 beneficial processes. The wound dressing of the present disclosure includes a backing layer affixed to a portal member for enhancing the effect of a vacuum wound therapy treatment.

The attached figures illustrate exemplary embodiments of the present disclosure and are referenced to describe the embodiments depicted therein. Hereinafter, the disclosure will be described in detail by explaining the figures wherein like reference numerals represent like parts
20 throughout the several views.

20

Referring initially to FIG. 1, a vacuum wound therapy system according to the present disclosure is depicted generally as 10 for use on a wound "w" surrounded by healthy skin "s." The vacuum wound therapy system 10 includes a vacuum system 12 in fluid communication with a vacuum reservoir 14 (FIG. 4) defined by or within wound dressing 16. The vacuum
5 system 12 includes a vacuum source 18 coupled to the dressing 16 through a one-way valve 20 and a suction device such as vacuum tube 24. A collection canister 28 may be provided for wound drainage and debris. The vacuum system 12 is adapted to provide a reduced pressure to the vacuum reservoir 14 appropriate to stimulate healing of the wound "w." A more detailed description of an appropriate vacuum system 12 is found in commonly assigned U.S. Patent
10 Application Publication 2007/0066946, the entire contents of which are incorporated herein by reference.

Wound dressing 16 generally includes a contact layer 34, filler 38 and a cover layer 40. Cover layer 40 includes a backing layer 44 and a portal member 46. Portal member 46 is configured to establish fluid communication between vacuum reservoir 14 and vacuum system
15 12 by providing an interface for a suction device such as vacuum tube 24. Each layer of wound dressing 16 is described in greater detail below.

Contact layer 34 may be sufficiently conformable to be positioned in direct contact with an irregularly shaped surface of a wound bed "w." A thin film of polyethylene or other suitable non-adherent material may form the contact layer 34 to limit the adherence of filler 38 and other
20 substances to the wound "w." Apertures or perforations in the film permit fluids to pass through the contact layer 34, allowing for the sub-atmospheric pressure to penetrate into the wound "w" and for exudates to flow freely out of the wound "w." By selecting an appropriate film material, the passage of wound exudate through contact layer 34 may be controlled so as to be

224

21

substantially unidirectional to prevent wound exudate from flowing back into the wound. To promote a unidirectional flow, a conical apertured film, such as VENTEX™ by Kendall Corp., a division of Covidien, or apertured films by Tredegar Film Products of Richmond, VA, may be selected for forming contact layer 34. Unidirectional flow of exudates may also be promoted by the selection of other materials including a lamination of layers having varying absorptive characteristics. One exemplary material, which may be used as a contact layer is sold under the trademark XEROFLO® by Kendall Corp., a division of Covidien.

Filler 38 may be arranged over contact layer 34 to fill wound "w" to the level of the surrounding healthy skin "s." An absorbent material such as non-woven gauze or reticulated foam may be used for filler 38 to trap any exudate that migrates through contact layer 34. An antimicrobial dressing sold under the trademark KERLIX® by Kendall Corp., a division of Covidien, may be suitable for use as filler 38. To prevent adhesion to the wound "w," the filler 38 may also comprise a material configured such that any stray fibers do not tend to protrude through apertures of contact layer 34 where they may become engulfed by newly forming granulation tissue. One particular type of material exhibiting this characteristic is often referred to as "tow." The manufacturing process for synthetic fibers often includes an extrusion of an indeterminate length of continuous filaments, which are spun together to form fibers. It is the continuous lengths of un-spun filaments which are referred to as tow. A single length of tow formed from a hydrophobic material such as polyolefin may be laid in the wound bed "w" to form filler 38. This arrangement allows for a complete removal of filler 38 when the dressing is changed without re-injuring the wound "w."

Cover layer 40 may be supplied as a single unit including both backing layer 44 and portal member 46, or alternatively, these items may be provided individually and assembled at

22

22

the time of installation over the wound "w." Cover layer 40 may be placed over the wound "w" enclosing the contact layer 34 and filler 38 therein.

Backing layer 44 may be formed from a flexible polymeric membrane or film to serve as a fluid barrier to allow for a sub-atmospheric pressure to be established in vacuum reservoir 14, and also as a microbial barrier preventing contaminants from entering the wound area. For example, backing layer 44 may comprise a polyurethane film having a thickness from about 0.8 mils to about 1.0 mils. Preferably, the backing layer 44 is formed from a moisture vapor permeable membrane to promote the exchange of oxygen and moisture vapor between the wound site and the atmosphere. One exemplary material is a transparent membrane sold under the trade name POLYSKIN® II by Kendall Corp., a division of Covidien. Other materials which may be suitable for use in a backing layer include the thin films marketed under the names TEGADERM™ by 3M of St. Paul, MN and OPSITE™ by Smith and Nephew PLC of London, UK.

The backing layer 44 of cover layer 40 is adapted to extend laterally beyond the perimeter of the wound bed "w" so as to contact the healthy skin "s" to form a seal thereto. To form the seal, backing layer 44 may be equipped with an adhesive coating on all, or any appropriate portion of a wound facing side. The adhesive coating may comprise, for example, a medical-grade, pressure-sensitive adhesive adapted to provide a fluid-tight and bacteria-tight seal around the wound "w." Thus exudate cannot escape through the edges of the dressing 16 and external air and contaminants may not enter the wound area. To provide such a seal, the adhesive coating may, for example, be in the range from about 1 mil to about 10 mils thick. In general, a high peel-strength adhesive may be used to resist inadvertent lift-off, roll or "flagging," i.e., a failure of the dressing to adhere to itself, at the edges of the cover layer 40.

61

The adhesive may include, for example, those adhesives included with the dressing sold under the trademark ULTEC® Hydrocolloid by Kendall Corp., a division of Covidien.

Backing layer 44 includes a connective region 50 to permit of connection of portal member 46. Connective region 50 receives a reservoir surface 54 of portal member 46 to fluidly isolate the reservoir surface 54 from an ambient surface 56 on the portal member 46 except through portal member 46. As illustrated in FIGS. 1 and 4, connective region 50 may be adapted to receive reservoir surface 54 directly such that an adhesive coating on either reservoir surface 54 or connective region 50 affixes the portal member 46 to the backing layer 44. Backing layer 44 defines a boundary between reservoir surface 54 and ambient surface 56. This arrangement permits isolation of reservoir surface 54 from reservoir 14, i.e. reservoir surface 54 may be disposed outside of reservoir 14. Perforations 58 may be formed through the connective region 50 to permit fluids to be drawn from reservoir 14. Alternatively, as illustrated in FIG. 5, backing layer 44a may include an entry 50a dimensioned such that a portion of portal member 46a protrudes through backing layer 44a. An appropriately positioned adhesive coating may form a seal between a wound facing side of backing layer 44a and an oppositely oriented surface of a flange 60a. This arrangement permits reservoir surface 54a to be positioned within reservoir 14a fluidly isolating reservoir surface 54a from ambient surface 56a. Other arrangements are contemplated for affixing a portal member 46, 46a to a backing layer 44, 44a, which may include other parts such as sealing rings (not shown).

Backing layer 44 may include an interrupted adhesive coating such that only the portions of backing layer 44 forming a seal are coated. For example, backing layer 44 may include a band of adhesive coating around the periphery to form a seal with the skin "s," and another band near the connective region 50 to form a seal with the portal member 46. An intermediate portion

24

of backing layer 44 may remain uncoated to limit the adherence of backing layer 44 to the filler 38, contact layer 34 or other surfaces. Such an arrangement may facilitate removal of the dressing 16 without re-injuring the wound "w."

Referring now to FIGS. 2 and 3, a portal member 46 may be formed as a rigid component, or alternatively portal member 46 may be molded from a flexible polymeric or elastomeric material. Flexibility in portal member 46 facilitates the placement of wound dressing 16 on curved areas of a patient's skin "s." Portal member 46 includes a reservoir surface 54 and an ambient surface 56. The reservoir surface 54 is adapted to be positioned such that a primary aperture 64 therein may fluidly communicate with vacuum reservoir 14, through a perforation 58 for example. Ambient surface 56 may be positioned in the environment surrounding dressing 16 and includes an opening 68 adapted for connection to a suction device such as vacuum tube 24 of vacuum system 12. A primary port 70 is defined between the primary aperture 64 and the opening 68 to permit fluid communication between the reservoir 14 and the vacuum system 12.

Branching from primary port 70 is a radial array of supplemental ports 72 extending to reservoir surface 54. Each of the supplemental ports 72 terminates at a supplemental aperture 74 distinct from and substantially spaced from primary aperture 64. Any number, distribution and arrangement of supplemental ports 72 may be included to distribute supplemental openings 74 over the reservoir surface 54. As FIG. 2 illustrates supplemental apertures 74 may be positioned near a periphery of reservoir surface 54 such that fluids may be drawn from reservoir 14 over a collection area spanning the entire area covered by the portal member 46. Any number, size and arrangement of primary and supplemental apertures 64, 74 is contemplated to effectively draw fluids for a particular application.

63

25

Referring now to FIG. 4, wound dressing 16 may be installed on a patient to cover a wound "w." Reservoir 14 is defined by or within wound dressing 16 when applied to the skin "s." Contact layer 34 is positioned in direct contact with the wound "w" and filler 38 is positioned up to the level of healthy skin "s." Portal member 46 may be positioned over
5 connective region 50 of backing layer 44 such that the primary and supplemental apertures 64, 74 are aligned with perforations 58. This will allow fluids to be drawn into primary and supplemental ports 70, 72 from reservoir 14. Ambient surface 56 is fluidly isolated from reservoir 14 except through primary and supplemental ports 70, 72. Opening 68 in the ambient surface 56 receives vacuum tube 24, thus fluidly connecting vacuum system 12 with reservoir
J 14.

Evacuating the reservoir 14 may impart a tendency for filler material 38 and wound exudate to migrate in the direction of airflow. This tendency for migration may result in the obstruction or occlusion of one or more of the primary and supplemental ports 70, 72. However, because portal member 46 may include many apertures 64, 74 distributed over the entire area
15 covered by the portal member 46, the effectiveness of the VWT procedure may persist. If one of the apertures 64, 74 becomes clogged, fluids will be drawn to another one of the apertures 64, 74 that is distinct and substantially spaced from the clogged aperture 64, 74.

Referring now to FIG. 5, an alternate embodiment of a vacuum wound therapy system is depicted generally as 10a. Wound dressing 16a includes a portal member 46a protruding
20 through entry 50a of cover layer 40a. Backing layer 44a adheres to the flange 60a of the portal member 46a and also to the skin "s" such that the reservoir surface 54a and ambient surface 56a are fluidly isolated except through the primary and supplemental ports 70a, 72a. Ambient surface 56a has an opening 68a therein for connection of a suction device such as vacuum tube

64

26

24. Fluid communication is thus established between reservoir 14a and vacuum system 12 through primary port 70a, and primary opening 64a. Supplemental ports 72a establish fluid communication between primary port 70a and supplemental apertures 74a in reservoir surface 54a. Supplemental apertures 74a are distinct and substantially spaced from primary aperture 64a. In this arrangement, reservoir surface 54a is enclosed by reservoir 14a.

Portal member 46a includes a radial array of supplemental ports 72a such that apertures 64a, 74a may be distributed substantially over the entire reservoir surface 54a. This arrangement provides a means of keeping a collection area of the port 46a exposed to as much of the dressing 16a as possible.

10 Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

65

22

What is claimed is:

1. A wound dressing comprising:

a backing layer for positioning over a wound to define a reservoir in which a reduced pressure may be maintained over the wound; and

5 a portal member affixed to the backing layer such that an ambient surface of the portal member may be fluidly isolated from a reservoir surface of the portal member, the backing layer defining a boundary between the ambient surface and the reservoir surface when the backing layer is positioned over a wound, the portal member comprising:

10 a primary port extending between an opening in the ambient surface and a primary aperture in the reservoir surface, the opening adapted for connection to a suction device and the primary aperture adapted for establishing fluid communication with the reservoir; and at least one supplemental port establishing fluid communication between the primary port and a supplemental aperture in the reservoir surface, the supplemental aperture distinct and substantially spaced from the primary aperture.

15 2. The wound dressing according to claim 1, wherein the at least one supplemental port includes a plurality of supplemental ports, each supplemental port extending radially outwardly from the primary port.

3. The wound dressing according to claim 1, wherein the at least one supplemental port includes a plurality of supplemental ports, each supplemental port extending between the 20 central port and a respective supplemental aperture in the reservoir surface, such that the primary and supplemental apertures are distributed substantially over the entire reservoir surface.

66

28

4. The wound dressing according to claim 1, wherein the portal member is molded from flexible polymeric or elastomeric material.

5. The wound dressing according to claim 1, wherein the portal member further comprises an attachment flange adapted for connection to the backing layer.

5 6. The wound dressing according to claim 1, wherein the backing layer comprises a flexible polymeric membrane.

7. The wound dressing according to claim 7, wherein the backing layer comprises an adhesive coating around a periphery thereof, the adhesive coating adapted to affix the backing layer over the wound and to provide a substantially fluid tight seal around the perimeter of the
10 wound.

8. The wound dressing according to claim 8, wherein the adhesive coating is interrupted such that an intermediate portion of the backing layer remains uncoated.

9. A vacuum wound therapy system comprising:
a contact layer adapted for positioning adjacent a wound bed;
15 an absorbent filler positioned adjacent the contact layer within the wound bed for collecting liquids exuding from the wound bed; and

a portal member affixed to a backing layer positioned over the wound bed to define a vacuum reservoir therebetween, the portal member including a primary port extending between an opening in an ambient surface and a primary aperture in a reservoir surface, the
20 portal member further including at least one supplemental port extending between the primary port and a supplemental aperture in the reservoir surface, the supplemental aperture distinct and substantially spaced from the primary aperture.

62

10. The vacuum wound therapy system according to claim 9, wherein the contact layer is formed from a conical apertured film.

11. The vacuum wound therapy system according to claim 9, wherein the absorbent filler material comprises a single strand of a polyolefin filament.

5 12. The vacuum wound therapy system according to claim 9, further comprising a vacuum system in fluid communication with the vacuum reservoir.

13. The vacuum wound therapy system according to claim 9, wherein the vacuum system includes a vacuum source, a collection canister and a one-way valve.

ABSTRACT

A wound dressing for use in a vacuum wound therapy treatment includes a backing layer for positioning over a wound to define a reservoir in which a reduced pressure may be maintained over the wound. A portal member affixed to the backing layer provides a connection to a reduced pressure source through an opening in an ambient surface. A primary port extends between the opening and a primary aperture in a reservoir surface to providing fluid communication between the reservoir and the reduced pressure source. At least one supplemental port establishes fluid communication between the primary port and a supplemental aperture in the reservoir surface that is distinct and substantially spaced from the primary aperture.

31

COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL,
DIVISIONAL, CONTINUATION OR CIP)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type: *(check one applicable item below)*

- ☒ original
☐ design
☐ supplemental

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application do not check next item; check appropriate one of last three items.

- ☐ national stage of PCT

NOTE: If one of the following 3 items apply then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR CIP.

- ☐ divisional
☐ continuation
☐ continuation-in-part (CIP)

INVENTORSHIP IDENTIFICATION

WARNING: If the inventors are each not the inventors of all the claims an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor *(if only one name is listed below)* or an original, first and joint inventor *(if plural names are listed below)* of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING

(Added Page to Combined Declaration and Power of Attorney
for Divisional, Continuation or CIP Application)
Page 1 of 6

20
240

3

SPECIFICATION IDENTIFICATION

the specification of which: *(complete (a), (b) or (c))*

- (a) ☒ is attached hereto.
- (b) ☐ was filed on _____ as ☐ Serial No. _____ or
☐ Express Mail No. _____, as Serial No. not yet known _____
and was amended on _____ *(if applicable)*.

NOTE: Amendments filed after the original papers are deposited with the PTO which contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 C.F.R. 1.67.

- (c) ☐ was described and claimed in PCT International Application No. _____ filed
on _____ and as amended under PCT Article 19 on _____ *(if any)*.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56, and

- ☐ in compliance with this duty there is attached an information disclosure statement in accordance with 37 C.F.R. §1.98.

PRIORITY CLAIM (35 U.S.C. §119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) ☒ no such applications have been filed.
- (e) ☐ such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Added Page to Combined Declaration and Power of Attorney
for Divisional, Continuation or CIP Application)
Page 2 of 6

247
71

33

**A. PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119(a)-(d)**

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
			☐ YES ☐ NO
			☐ YES ☐ NO
			☐ YES ☐ NO

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. §119(e))**

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE

**ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

NOTE: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CIP APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. §120.

(Added Page to Combined Declaration and Power of Attorney
for Divisional, Continuation or CIP Application)
Page 3 of 6

242

34

POWER OF ATTORNEY

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

ALL ATTORNEYS AND REGISTERED PRACTITIONERS ASSOCIATED WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE, CUSTOMER NO. 55825.

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:
Joseph W. Schmidt, Esq.

Carter, DeLuca, Farrell & Schmidt, LLP
445 Broad Hollow Road – Suite 225
Melville, New York 11747
Tel.: (631) 501-5700
Fax: (631) 501-3526

(631) 501-5700

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Added Page to Combined Declaration and Power of Attorney
for Divisional, Continuation or CIP Application)
Page 4 of 6

243

73

39

SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name as it should appear on the filing receipt and all other documents.

Full Name of sole or first inventor: Mark A. Vess

Inventor's signature: Mark A. Vess Date: 03-06-08

Residence: 303 High Street, Hanson, MA 02341

Country of Citizenship: US

Mailing Address: Same as above

(Added Page to Combined Declaration and Power of Attorney
for Divisional, Continuation or CIP Application)
Page 5 of 6

249

36

**CHECK PROPER BOX(ES) FOR ANY OF THE FOLLOWING
ADDED PAGE(S) WHICH FORM A PART OF THIS DECLARATION**

- ☐ Signature for subsequent joint inventors.
Number of pages added ____.
- ☐ Signature by administrator(trix), executor(trix) or legal representative for deceased or
incapacitated inventor.
Number of pages added ____.
- ☐ Signature for inventor who refuses to sign or cannot be reached by person authorized under
37 C.F.R. §1.47.
Number of pages added ____.

- ☐ Added pages to combined declaration and power of attorney for divisional, continuation,
or continuation-in-part (CIP) application.
Number of pages added ____.

- ☐ Authorization of attorney(s) to accept and follow instructions from representative.

If no further pages form a part of this Declaration then end this Declaration with this page
and check the following item.

☒ This declaration ends with this page.

(Added Page to Combined Declaration and Power of Attorney
for Divisional, Continuation or CIP Application)
Page 6 of 6

245
75

37

1/3




FIG. 1

247
76

30

2/3




FIG. 2




FIG. 3

267
77

3/3




FIG. 4




FIG. 5

40

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	HKN-01015 (1502-323)
		Application Number	
Title of Invention	WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--

Applicant Information:

Applicant 1					Remove
Applicant Authority ☒ Inventor		☐ Legal Representative under 35 U.S.C. 117		☐ Party of Interest under 35 U.S.C. 118	
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Mark	A.	Vess		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Hanson	State/Province	MA	Country of Residence i	US
Citizenship under 37 CFR 1.41(b) i		US			
Mailing Address of Applicant:					
Address 1		303 High Street			
Address 2					
City	Hanson	State/Province	MA		
Postal Code	02341	Countryi	US		
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.					
Add					

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).	
☐ An Address is being provided for the correspondence Information of this application.	
Customer Number	55825
Email Address	
Add Email	
Remove Email	

Application Information:

Title of the Invention	WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING		
Attorney Docket Number	HKN-01015 (1502-323)	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)	3	Suggested Figure for Publication (if any)	

244
209

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	HKN-01015 (1502-323)
	Application Number	
Title of Invention	WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING	

Publication Information:

☐	Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐	Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.

Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	55825		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status		Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the [Add](#) button.

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

		Remove	
Application Number	Country i	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
			☒ Yes ☐ No

Additional Foreign Priority Data may be generated within this form by selecting the [Add](#) button.

Assignee Information:

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.

Assignee 1	Remove
------------	------------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	HKN-01015 (1502-323)
		Application Number	
Title of Invention	WOUND DRESSING PORT AND ASSOCIATED WOUND DRESSING		

If the Assignee is an Organization check here. ☒			
Organization Name	Tyco Healthcare Group LP		
Mailing Address Information:			
Address 1	15 Hampshire Street		
Address 2			
City	Mansfield	State/Province	MA
Country ⁱ	US	Postal Code	02048
Phone Number		Fax Number	
Email Address			
Additional Assignee Data may be generated within this form by selecting the Add button. Add			

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.					
Signature	/joseph w. schmidt/		Date (YYYY-MM-DD)	2008-03-07	
First Name	Joseph W.	Last Name	Schmidt	Registration Number	36920

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

2020
Bogotá D.C.,

Doctor(a)
CORREA ORDOÑEZ ALVARO
Apoderado(a) y/o Representante de
TYCO HEALTHCARE GROUP LP

REFERENCIA	Radicación No. 9 22193
	Trámite 2
	Evento 1
	Actuación 416
	Oficio No. 10396
	Folios 1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

De acuerdo con lo previsto por el artículo 40 de la Decisión 486/00, la publicación en este caso se hará a partir del día 04 del mes de septiembre de 2010.

Cúmplase
Dado en Bogotá DC,

11 1 MAYO 2010

ALIX CARMENZA GESPEDES DE VERGEL
Directora de Nuevas Creaciones (c)

jfernand